Bridging Therapy Responses May Outcomes With Axi-Cel ...

Bridging therapy before axicabtagene ciloleucel (axi-cel) for relapsed/refractory large B-cell lymphoma (LBCL) did not improve efficacy or safety outcomes, per a CIBMTR analysis. Adjusted analyses showed no significant differences in outcomes between bridging and non-bridging therapy groups, despite initial disparities in response rates and survival metrics.